Search results for "Bio"

Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors

Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors

Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE." Derived from the opening of its international nonproprietary...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
French Cardiac Surgeon Brings Father 10,000 km to Seoul for Rare Dual-Donor Liver Transplant

French Cardiac Surgeon Brings Father 10,000 km to Seoul for Rare Dual-Donor Liver Transplant

When Mohamed El Kettani, a 64-year-old Moroccan-born dual citizen of France and Morocco, was told that a liver...
10 Reasons Grapes Are Good for You—Even If You Have Diabetes

10 Reasons Grapes Are Good for You—Even If You Have Diabetes

A single grape may be small, but it packs a powerful nutritional punch. Rich in essential vitamins, minerals, and...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment

The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment

For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Medical AI Can Explain Its Decisions—but Can Clinicians Trust Its Reasons?

Medical AI Can Explain Its Decisions—but Can Clinicians Trust Its Reasons?

Artificial intelligence in medical imaging can analyze brain magnetic resonance imaging scans not only to estimate...
EZH1 Mutation 'Locks' Cancer-Fighting Genes to Fuel Thyroid Tumors, Study Finds

EZH1 Mutation 'Locks' Cancer-Fighting Genes to Fuel Thyroid Tumors, Study Finds

Cancer cells do not grow simply by switching on genes that drive proliferation; they can also lock away genes that keep...